<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01691053</url>
  </required_header>
  <id_info>
    <org_study_id>MN0511_1</org_study_id>
    <secondary_id>2011-003179-12</secondary_id>
    <secondary_id>01KG1202</secondary_id>
    <nct_id>NCT01691053</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Receptor Antagonists in End Stage Renal Disease</brief_title>
  <acronym>MiREnDa</acronym>
  <official_title>Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center Wuerzburg (CTCW)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality.
      Cardiovascular (CV) causes account for almost half of all-cause mortality. Increased left
      ventricular mass (LVM) is a common finding in ESRD patients on dialysis and is an independent
      predictor of survival. Yet, to date there is no established medical treatment to reduce CV
      morbidity and mortality in ESRD patients on hemodialysis. Blockade of aldosterone action by
      means of mineralocorticoid receptor antagonists (MRA) provides cardioprotection and improves
      outcome in heart failure patients. Furthermore, the MRA spironolactone has recently been
      shown to reduce LVM in patients with mild-to-moderate chronic kidney disease (CKD). The
      investigators here hypothesize that spironolactone treatment is cardioprotective by reducing
      LVM in ESRD patients on dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Mass Index</measure>
    <time_frame>9 months</time_frame>
    <description>as assessed by cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac function parameters</measure>
    <time_frame>9 months</time_frame>
    <description>cardiac volumes, systolic and diastolic function, cardiac output as measured by cardiac MRI and echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office and 24h blood pressure</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical measures of heart failure severity</measure>
    <time_frame>9 months</time_frame>
    <description>New York Heart Association (NYHA) functional class, 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function</measure>
    <time_frame>9 months</time_frame>
    <description>Carotid intima meda thickness, pulse wave analysis, carotid artery distensibility, flow mediated dilatation of the brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of heart failure, inflammation and fibrosis</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and/or hospitalization for heart failure</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures</measure>
    <time_frame>9 months</time_frame>
    <description>Pre-dialysis potassium levels, frequency of hyperkalemic episodes (K&gt;6.5mmol/l), measurement of residual kidney function (if applicable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>End Stage Renal Disease / Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>50mg once daily</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Hemodialysis treatment for at least 3 months

          -  At least 3 dialysis sessions per week

          -  Written informed consent

        Exclusion Criteria:

          -  Contraindications for cardiac magnet resonance imaging (CMR)

          -  Mineralocorticoid receptor antagonist treatment within the last 6 months

          -  Estimated life expectancy &lt; 12 months as judged by the nephrologist

          -  History of hyperkalemia, defined as pre-dialysis potassium &gt; 6.5 mmol/l occurring ≥ 3
             times within the last 3 months prior to enrolment.

          -  High risk to develop hyperkalemia defined as pre-dialysis potassium &gt; 6.0 mmol/l

          -  Hypotension (systolic blood pressure &lt; 100 mmHg)

          -  Planned kidney transplantation (living donor) within the prospected study duration

          -  Any acute illness within the last 4 weeks precluding a study participation as judged
             by the nephrologist

          -  Non-amenorrheic women with child bearing potential without reliable contraception,
             pregnancy/lactation

          -  Allergy/hypersensitivity to spironolactone

          -  Non-compliance suspected or demonstrated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Wanner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Wuerzburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabian Hammer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Wuerzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>September 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2012</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage renal disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>Left ventricular hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

